TABLE 5.
Effects of drug treatment on blood lymphocyte subsets in HuCD4/Tg mice challenged with B16F11 melanoma tumor cells
| Treatment | Absolute lymphocytesa (cells/μl [mean ± SD]) | CD2+ CD3+ DX5+ (NK) cells
|
CD2+ CD4+ CD8− cells
|
CD2+ CD4− CD8+ cells
|
|||
|---|---|---|---|---|---|---|---|
| (%) | (Cells/μl) | (%) | (Cells/μl) | (%) | (Cells/μl) | ||
| Vehicle | 8,227 ± 733 | 6.4 | 527 | 27.7 | 2,279 | 23.0 | 1,892 |
| Keliximab (25 mg/kg) | 6,606 ± 771 | NDb | ND | 5.9 | 390 | 27.1 | 1,790 |
| Keliximab (250 mg/kg) | 6,357 ± 352 | ND | ND | 0.9 | 57 | 29.8 | 1,894 |
| AAGM-1 | 3,806 ± 393 | 4.0 | 152 | 32.1 | 1,228 | 22.9 | 872 |
| Thy1.2 | 4,183 ± 237 | 8.0 | 335 | 1.3 | 54 | 1.4 | 59 |
a
Analysis was performed within 48 h after tumor cell injection.
b
ND, not done.